AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03229954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate(Feroba-YOU) per oral
Description: 160 mg/day of ferrous sulfate (Feroba-YOU) will be taken per oral for 12 weeks.
Study NCT01229761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cotrimoxazole prophylaxis
Description: 100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months
Study NCT01229761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cotrimoxazole placebo
Description: 100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months
Study NCT01229761 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exclusive breastfeeding until 6 months of age
Description: Breastfeeding for 6 months, followed by formula feeding for 6 month. Breastfeeding infants will be prophylaxed with maternal highly active antiretroviral therapy (HAART) (if available) or with infant nevirapine.
Study NCT01229761 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: breastfeeding for 12 months
Description: Breastfeeding infants will be prophylaxed with maternal HAART (if available) or with infant nevirapine.
Study NCT02614716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3090106
Description: Administered SC
Study NCT02614716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT03919383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing
Study NCT03919383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg intravenously every 3 weeks
Study NCT01147224 — intervention group
Intervention type: DRUG
Intervention: Alvesco
Description: This is an observational study. Therefore, the physician decides about dosage according to individual needs.
Study NCT04163705 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample collection
Description: Routine Laboratory Analysis
Study NCT03430674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise, questionnaires and blood draws.
Study NCT02071173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUITY X4 quadripolar coronary venous lead and RELIANCE 4-FRONT defibrillation lead
Description: The ACUITY X4 leads are intended for chronic left ventricular pacing and sensing. The leads have 3 tip configuration designs (straight tip, short tip spiral, and long tip spiral), which is intended to provide choices for patients with different anatomies.~The RELIANCE 4-FRONT leads are designed for right-side heart applications within the ventricle, atrium, and superior vena cava. It is intended for permanent sensing, pacing, and defibrillation when used with a compatible implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D).~Subjects were allowed to receive both the ACUITY X4 and RELIANCE 4-FRONT lead.
Study NCT01292928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent implantation
Description: Stent implantation during the index procedure.
Study NCT01838798 — intervention group
Intervention type: OTHER
Intervention: Baseline activities
Description: Initial consent procedures and baseline data collection.
Study NCT01838798 — intervention group
Intervention type: OTHER
Intervention: Clinical interview with a psychologist
Description: Clinical interview with a psychologist.~This interview with a psychologist will take place after patient consent procedures, and at least 2 days after discontinuation of sedation, and before leaving the ICU. This interview will include:~* An inventory of peritraumatic distress symptoms~* A questionnaire on peritraumatic dissociative experiences~* An assessment of related, potential impacts~* The HADS questionnaire
Study NCT01838798 — intervention group
Intervention type: OTHER
Intervention: Telephone interview 2 months after ICU discharge
Description: At 2 months after leaving the ICU, a psychologist will contact the patient with questions regarding his/her representation of hospitalization. This implies the following:~* Questionnaires assessing memories and stressors (Questionnaires ICUMT, and ICU-SEQ~* An assessment of psychological trauma~* An assessment of potential impacts
Study NCT01838798 — intervention group
Intervention type: OTHER
Intervention: Clinical interview with a psychologist
Description: At 4 months after ICU discharge, the patient has a clinical interview during which a psychologist will:~* assess cognitive functions~* evaluate clinical symptoms of depression~* assess quality of life~* assess symptoms of post traumatic stress
Study NCT02833168 — intervention group
Intervention type: OTHER
Intervention: patient-filled questionnaires
Description: All patients answer selected questionnaires on sleep-related symptoms, sleep quality, daytime performance, and health-related quality of life.
Study NCT02833168 — intervention group
Intervention type: DEVICE
Intervention: spiromanometry
Description: Measurement of forced vital capacity, maximum inspiratory pressure and maximum expiratory pressure
Study NCT04223518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Serum bovine immunoglobulin
Description: Serum bovine immunoglobulin (SBI), also known by the brand name of Enteragam (Proliant Biologicals, Ankeny, Iowa) is derived from bovine serum and classified as a medical food composed of >90% protein which consists primarily of immunoglobulins (>50% of IgG) along with other bovine proteins and peptides similar to those commonly consumed by humans in beef products.
Study NCT04223518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hydrolyzed Collagen
Study NCT04461002 — intervention group
Intervention type: OTHER
Intervention: Retrospective analysis
Description: Evaluate the correlation between tumour molecular profile and preoperative imaging data (FDG and FDOPA PET-scan and multimodal MRI).
Study NCT04720079 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous infiltration of intercostobrachial nerve
Description: Preoperative subcutaneous infiltration of intercostobrachial nerve with 10ml of 0.5% ropivacaine
Study NCT04720079 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T2 paravertebral nerve block
Description: Preoperative ultrasound guided T2 paravertebral nerve block with 10ml of 0.5% ropivacaine
Study NCT02952352 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes Prevention Program
Description: Culturally adapted diabetes prevention program
Study NCT02952352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program
Description: Culturally adapted diabetes prevention program
Study NCT01788748 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bipolar radiofrequency and infrared
Study NCT01788748 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fractional bipolar radiofrequency
Study NCT00574587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat 200 or 300 mg PO BID on days 1-3 of each weekly paclitaxel dose
Study NCT00574587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 weekly for 12 weeks
Study NCT00574587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose
Study NCT00574587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks
Study NCT00574587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks
Study NCT00574587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical excision of tumor from breast
Study NCT02189551 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gait training with Lokomat Pro
Study NCT02189551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait training with Lokomat Pro FreeD
Study NCT05368779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The internet-based psychosocial intervention
Description: Participants were provided psychoeducation on intimate partner abuse, psychological trauma, Social Learning Theory, and Cognitive Behavioral Therapy methods. Intimate partner abuse and psychological trauma were discussed in the context of sociocultural factors. Cognitive Behavioral Therapy approaches were used to attempt to normalize intimate partner abuse, psychological trauma and their effects on participants. Participants were exposed to trauma gradually with record of sessions watching and imaginary exposure methods for reducing avoidance behaviours. Schemas, intermediate beliefs, and automatic thoughts of participants were studied using Cognitive Behavioral Therapy approaches and cognitive restructuring was fulfilled. The universality of mental pain, the meaning of life, the integrate trauma into life histories of participants, expectations for the future romantic relationships, and post traumatic growth were all discussed in accordance with the goals and values of participants.
Study NCT01692782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-225289
Description: SEP-225289 4mg once daily
Study NCT01692782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-225289
Description: SEP-225289 8mg once daily
Study NCT01692782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study NCT01945606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (treatment 1)
Description: Oral administration of placebo tablets
Study NCT01945606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1067197 (treatment 2)
Description: Oral administration of a single dose of 30 mg (3×10 mg Tablet) BAY1067197
Study NCT02769286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring EGFR mutations (cohort 1) and those harboring T790M (cohort 2) which were detected from circulating tumor DNA
Study NCT03686852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: same medications but different dosages
Description: The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 50IU (Group A), 150IU (Group B) or 250IU (Group C) of recFSH (Puregon®, MSD)
Study NCT02490059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bronchoscopy
Description: Bronchoscopy for diagnosis of pulmonary nodules
Study NCT01717456 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily diary
Description: Both groups will keep a daily diary, but amount of detail differs: Active comparator group records bowel accidents, bowel movements, Bristol Stool ratings of stool consistency, number of times they do pelvic floor exercises, study medications, and comments for the nurse to read. Placebo comparator group records only bowel accidents, bowel movements, and Bristol Stool scores.
Study NCT01717456 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Daily diary
Description: Both groups will keep a daily diary, but amount of detail differs: Active comparator group records bowel accidents, bowel movements, Bristol Stool ratings of stool consistency, number of times they do pelvic floor exercises, study medications, and comments for the nurse to read. Placebo comparator group records only bowel accidents, bowel movements, and Bristol Stool scores.
Study NCT01717456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protective pads or garments
Description: In both groups, patients will be permitted to use pads or protective garments to avoid embarrassment. They will be told that fecal leakage that is stopped by a pad or protective garment should still be recorded as fecal incontinence.
Study NCT01717456 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Protective pads or garments
Description: In both groups, patients will be permitted to use pads or protective garments to avoid embarrassment. They will be told that fecal leakage that is stopped by a pad or protective garment should still be recorded as fecal incontinence.
Study NCT04013256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette Smoke
Description: Cigarette smoke, generated by a smoking machine and aged is used to reproduce exposure to secondhand and thirdhand cigarette smoke.
Study NCT04013256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette Smoke
Description: Cigarette smoke, generated by a smoking machine and aged is used to reproduce exposure to secondhand and thirdhand cigarette smoke.
Study NCT03391674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation through oral capsules after omeprazole pre-treatment
Study NCT01016210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuveris
Description: IV
Study NCT01016210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuveris
Description: All recruited women will be treated similarly employing the recombinant FSH and the fixed GnRH antagonist. Concomitantly, on the same day of the antagonist administration r-LH will be administered daily and continued until human chorionic gonadotropin (hCG) day.
Study NCT04149405 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phase 1 periodontal therapy
Description: Scaling and root planning with ultrasonic and hand instruments under local anesthesia.
Study NCT04149405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisphosphonate therapy
Description: Using aclasta: intravenous infusion of 5 mg of zoledronic acid once a year
Study NCT00952367 — intervention group
Intervention type: OTHER
Intervention: Nasopharyngeal swab
Description: Nasopharyngeal swab
Study NCT00195910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.1 mg/kg IV morphine
Study NCT00195910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 0.015 mg/kg IV hydromorphone
Study NCT04161508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Injection
Description: injection of sugammadex for the reversal of neuromuscular blockade at the end of the surgery
Study NCT04161508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine Injection
Description: injection of neostigmine for the reversal of neuromuscular blockade at the end of the surgery
Study NCT02871648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
Study NCT02871648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludrocortisone
Description: Fludrocortisone 0.1 mg
Study NCT02871648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Epleronone 100 mg
Study NCT00898885 — intervention group
Intervention type: PROCEDURE
Intervention: oral biopsy
Description: oral mucosa and salivary gland biopsy after bone marrow transplantation
Study NCT04357327 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: rapid salivary test
Description: a rapid salivary test to detect SARS-CoV-2 spike protein in saliva with a lateral flow immunoassay
Study NCT04357327 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: rapid salivary test
Description: a rapid salivary test to detect SARS-CoV-2 spike protein in saliva with a lateral flow immunoassay
Study NCT03902054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three-dose regimen of high dosage investigational sIPV
Description: The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..
Study NCT03902054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three-dose regimen of medium dosage investigational sIPV
Description: The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..
Study NCT03902054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three-dose regimen of low dosage investigational sIPV
Description: The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..
Study NCT03902054 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Three-dose regimen of commercialized sIPV
Description: The control vaccine was manufactured by Chinese Academy of Medical Sciences.
Study NCT03902054 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Three-dose regimen of commercialized IPV
Description: The control vaccine was manufactured by Sanofi Pasteur S.A (IMOVAX POLIO).
Study NCT02099474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study of pharmacokinetic properties of raltegravir during the 3rd trimester of pregnancy
Description: Introduction of a catheter for performing 5 blood samples in pregnant women infected by HIV-1, before the raltegravir intake, 0.5, 3, 8 and 12 hours after the intake at each of two visits (between 30 and 37 weeks of amenorrhea, and 4 to 6 weeks after delivery)
Study NCT03763708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Programming
Study NCT04013256 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Clean Air and Clean Clothing/Sham exposure
Description: Clean air, created by high-efficiency particulate air (HEPA) and charcoal filtration and temperature and humidity control.~Clean cotton clothing.
Study NCT02159859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: Subjects are hemodialysis patients who are admitted to Oakwood Hospital - Dearborn
Study NCT04255459 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Moist Snuff
Description: Moist Snuff product
Study NCT04255459 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Camel Snus
Description: Camel Snus product
Study NCT04255459 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cigarettes
Description: Cigarette product
Study NCT04255459 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No tobacco usage
Description: No tobacco usage
Study NCT04882111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ALIGN
Description: The ALIGN intervention was developed by the Holding Group, an independent partnership of palliative care-trained social workers. The intervention is theory driven, patient/caregiver centered, addresses palliative care and psychosocial issues, and integrates with health care teams. Working in collaboration with KPCO and Dr. Stacy Fischer (primary mentor), the Holding Group tested the ALIGN intervention in the LTAC and SNF setting (Preliminary Studies). The Holding Group will be the intervention personnel providing psychosocial care that targets communication, goal alignment, and caregiver support.
Study NCT01271114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline and Terlipressin
Description: Hypertonic saline 3% 7mL/Kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation more than 10%; Terlipressin infusion (dilution 1mg in 100mL) triggered by MAP below 70 mmHg for a goal MAP above 70 mmHg
Study NCT01271114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline and norepinephrine
Description: Normal saline IV bolus 7mL/kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation above 10%; Norepinephrine drip (80 micrograms/mL) to keep MAP at least 70 mmHg
Study NCT01861327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CO2
Description: carbon dioxide (CO2) as arterial contrast media
Study NCT01861327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine contrast media
Description: Iodine as arterial contrast media
Study NCT03346395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem solving based intervention
Description: Problem solving based intervention
Study NCT03346395 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: Medical treatment, or behavioral therapy or a coordination of behavioral therapy and medical treatment. Meeting with a rehabilitation coordinator.
Study NCT03491878 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Three dimensional laparoscopic
Description: Three dimensional laparoscopic cholecystectomy including segments IVB and V
Study NCT03491878 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open
Description: Open cholecystectomy including segments IVB and V
Study NCT00631111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: effervescent ibuprofen tablets
Study NCT00631111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: effervescent Aspirin plus Vitamin C tablets
Study NCT00631111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen tablets
Study NCT00631111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo